FDA Launches Performance Bonuses to Accelerate Drug Review Timelines
The U.S. Food and Drug Administration is introducing a new incentive program that provides financial bonuses to staff members who complete drug application reviews ahead of schedule. This move aims to streamline the regulatory pipeline and reduce the backlog of pending therapies, though it raises questions regarding the balance between speed and clinical rigor.